CDK9 and cancer: Intriguingly, the combination of TRAIL with CDK9 inhibition provides for a pro-apoptotic therapy which is not only broadly applicable but also capable of broadly bypassing cancer therapy resistance, importantly independently of whether the resistance is primary or acquired and, when it is acquired, independently of how the resistance was achieved [133].